Lurasidone is a new atypical antipsychotic drug that acts mainly through high-affinity binding to dopamine D2 receptors and 5-hydroxytryptamine 5-HT2A receptors, and is used clinically for the treatment of schizophrenia and bipolar disorder (34). The gene discussed is DRD2; the disease is schizophrenia.